Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of four components: anti-D (Rho(D) immune globulin), intravenous immunoglobulin, methylprednisolone, and vincristine. This combination is likely used in the treatment of immune thrombocytopenic purpura (ITP) or other hematological disorders. Anti-D (Rho(D) immune globulin) is used to treat immune thrombocytopenic purpura in Rh-positive patients by binding to the D antigen on red blood cells. Intravenous immunoglobulin works by modulating the immune response. Methylprednisolone is a corticosteroid that reduces inflammation and suppresses the immune system. Vincristine is a vinca alkaloid that inhibits microtubule assembly and is used as an antineoplastic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-D + intravenous immunoglobulin + methylprednisolone + vincristine.